When compared with the more prevalent Invasive Ductal Carcinoma (IDC), its distinctive features include older age at diagnosis, large tumor size, compromised lymph node status as well as increased LVI, estrogen receptor (ER), and Human Epidermal growth factor Receptor 2 (HER-2) positivity rates.[5] A 2019 study by Lewis[6] on 2660 pure IMPC patients revealed that approximately 55.2% of patients showed regional LNM at the time of diagnosis. This evidence concerns the gene ERBB2 and breast ductal adenocarcinoma.